Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.
Acinetobacter baumannii
antibiotic resistance
bloodstream infections
cefiderocol
colistin
multidrug resistance
pneumonia
sepsis
ventilator-associated pneumonia
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
17 05 2022
17 05 2022
Historique:
pubmed:
22
3
2022
medline:
20
5
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, but clinical data are limited. This is an observational retrospective study conducted in the University Hospital of Pisa including consecutive patients with CRAB infections (January 2020 to August 2021). Patients were divided in two study groups according to the antibiotic treatment received: cefiderocol- and colistin-containing regimens. The primary outcome was the 30-day mortality. A Cox regression analysis was performed to identify factors independently associated with 30-day mortality. A propensity score analysis using inverse probability of treatment weighting (IPTW) was also performed. A total of 124 patients were included: 47 (37.9%) received cefiderocol, while 77 (62.1%) colistin-containing regimens. Overall, 79 (63.7%) patients had a bloodstream infection (BSI), 35 (28.5%) a ventilator-associated pneumonia (VAP) and 10 (8.1%) other infections. Thirty-day mortality was higher in patients receiving colistin- compared to those who received cefiderocol-containing regimens (55.8% versus 34%,
Identifiants
pubmed: 35311522
doi: 10.1128/aac.02142-21
pmc: PMC9112922
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Cephalosporins
0
Colistin
Z67X93HJG1
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0214221Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Références
Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601
pubmed: 24982065
J Antimicrob Chemother. 2019 Jul 1;74(7):1971-1974
pubmed: 31220260
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32868330
Nat Microbiol. 2019 Oct;4(10):1627-1635
pubmed: 31209306
Antibiotics (Basel). 2021 May 29;10(6):
pubmed: 34072342
Sci Rep. 2015 Nov 24;5:17091
pubmed: 26597507
Antimicrob Agents Chemother. 2015 Dec;59(12):7743-52
pubmed: 26438502
Lancet Infect Dis. 2021 May;21(5):597-598
pubmed: 33894839
Int J Antimicrob Agents. 2012 Feb;39(2):180-1
pubmed: 22100281
Infection. 2022 Feb;50(1):83-92
pubmed: 34176088
Stat Med. 2015 Dec 10;34(28):3661-79
pubmed: 26238958
Clin Microbiol Infect. 2014 Dec;20(12):O1028-34
pubmed: 24930471
Clin Infect Dis. 2012 Jun;54(12):1699-709
pubmed: 22467668
Clin Infect Dis. 2021 Jun 1;72(11):1871-1878
pubmed: 32427286
Clin Infect Dis. 2021 Jun 1;72(11):2021-2024
pubmed: 32941593
Lancet Infect Dis. 2021 Feb;21(2):226-240
pubmed: 33058795
Lancet Infect Dis. 2018 Apr;18(4):391-400
pubmed: 29456043
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721
pubmed: 34252309
Ann Clin Microbiol Antimicrob. 2017 Apr 5;16(1):24
pubmed: 28381268
J Antimicrob Chemother. 2021 Mar 12;76(4):1078-1084
pubmed: 33374002
Int J Antimicrob Agents. 2013 May;41(5):463-7
pubmed: 23537581
Res Social Adm Pharm. 2006 Mar;2(1):143-51
pubmed: 17138506
J Antimicrob Chemother. 2018 Jan 01;73(1):22-32
pubmed: 29069421
Crit Care. 2020 Jun 5;24(1):289
pubmed: 32503590
Nephron Clin Pract. 2012;120(4):c179-84
pubmed: 22890468
Epidemiol Infect. 2013 Jun;141(6):1214-22
pubmed: 22954403
Crit Care. 2020 Jan 30;24(1):29
pubmed: 32000834
J Antimicrob Chemother. 2021 Oct 11;76(11):2902-2905
pubmed: 34383901
Infection. 2021 Dec;49(6):1149-1161
pubmed: 34260054
Clin Microbiol Infect. 2022 Feb;28(2):298.e1-298.e7
pubmed: 34197935
Clin Microbiol Infect. 2018 Aug;24(8):801-802
pubmed: 29649600
PLoS One. 2011 Mar 31;6(3):e18174
pubmed: 21483818